Compare Amgen, Inc. (AMGN) vs MGM Resorts International (MGM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs MGM Resorts International — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while MGM Resorts International trades at $47.25 (market cap $11.99B). The key difference: Amgen, Inc. is far larger — about 16.4× MGM Resorts International's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MGM | |
|---|---|---|
Market Cap | $196.12B | $11.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $50.69 |
52-Week Low | $271.18 | $30.72 |
Enterprise Value | $241.41B | $41.04B |
Dividend Yield | 2.77% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MGM Resorts International (MGM) trades at $46.88, up 0.95% on the day, with a bullish technical signal and mixed earnings history. The stock shows strong revenue growth from $13.1B in 2022 to $17.5B in 2025, though net income margins have compressed to 1.03%. Recent news highlights potential acquisition talks with Barry Diller at $48.30 per share, while analyst consensus is evenly split between Buy and Hold ratings.
Outlook: MGM offers exposure to gaming and hospitality recovery with a reasonable P/S of 0.71, but high P/E of 64.22 reflects margin pressures. Risks include earnings volatility, debt levels, and regulatory scrutiny. The Diller bid provides near-term upside potential, but execution on profitability remains key for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
